INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ
Tesi recently reported positive preliminary data from the company’s INB03 Phase
I clinical trial in cancer patients during a presentation at Cambridge
Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://ibn.fm/m1Iy3). An article
discussing the company reads, “‘The goal of the Phase I study is to determine,
in order of priority, the safety of INB03 in cancer patients, the dose of INB03
to take into the Phase II trials in cancer, and evidence of a biologic effect
of INB03,’ stated Tesi, who is also INmune Bio’s chief medical officer. ‘All of
these goals have been met. Using data from this trial, we have begun planning a
Phase II trial using INB03 as part of combination immunotherapy in patients
with cancer.’ . . . The Phase I trial is an open-label, dose-escalation trial
in patients with advanced solid tumors. Patients received INB03, a novel,
second-generation soluble TNF (tumor necrosis factor) inhibitor that works by
leveraging a dominant-negative technology. Positive preliminary data from the
first two cohorts were released. That data will be followed by a final report
later this year as the company advances the program into a Phase II study.”
To view the full article, visit http://ibn.fm/Yv3yZ
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB)
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that reengineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual disease,
the remaining cancer cells that are difficult to detect, which often cause
relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often
cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors.
XPro1595 targets neuroinflammation, which causes microglial activation and
neuronal cell death. INmune Bio’s product platforms utilize a precision
medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
